Tyrosine Kinase
Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.
Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.
- B1103 Mutant EGFR inhibitorSummary: Selective Mutated EGFR inhibitor
- B1496 IcotinibSummary: EGFR tyrosine kinase inhibitor
- B1104 AZD-92911 CitationTarget: EGFRSummary: Mutated forms EGFR inhibitor
- B1105 AZD-9291 mesylateSummary: third generation EGFRm inhibitor, oral and irreversible
- A3967 Lapatinib DitosylateTarget: EGFR|ErbB-2Summary: EGFR/HER2 inhibitor,potent and selective
- A8218 Lapatinib2 CitationTarget: ErbBSummary: EGFR/HER2 inhibitor,potent,selective and reversible
- A8219 Gefitinib (ZD1839)3 CitationTarget: EGFRSummary: Selective EGFR inhibitor
- A8234 Erlotinib Hydrochloride2 CitationSummary: Selective EGFR inhibitor
- A8247 Afatinib (BIBW2992)1 CitationTarget: EGFRSummary: Irreversible EGFR/HER2 inhibitor
- A1389 WZ4002Summary: Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent